A high-affinity anti-IL-6 antibody, MEDI5117, has been shown to enhance the anti-tumor efficacy of chemotherapy in several types of tumors that are known to be driven by the IL-6–STAT-3 signaling [120]. Here, STAT3 is linked to neoplasm.